Clinical trials: Coronary Patient
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen
Angina Pectoris
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
- Trial name
- T89 phase 2 (NCT00797953)
- Testing
- T89
- Where
- 15 sites in United States
- Volunteers
- 124 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Ventricular Fibrillation, Ventricular Tachycardia
Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function
Re-hospitalizations or deaths by worsening heart failure are often preceded by distinct trends of clinical parameters such as atrial or ventricular arrhythmia, activity, heart rate variability, or ventricular ectopy.
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Congestive Heart Failure
- Trial name
- IN-TIME (NCT00538356)
- Testing
- ICD or CRT-D with Home Monitoring feature deactivated, ICD or CRT-D with Home Monitoring feature activated
- Where
- 39 sites in Australia, Austria and 5 more
- Volunteers
- 720 people
- Sponsor
- Biotronik SE & Co. KG
Patent Ductus Arteriosus
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects…
- Trial name
- NCT05264753
- Testing
- Occlutech® PDA Occluder
- Where
- 15 sites in Canada, France and 7 more
- Volunteers
- 255 people
- Sponsor
- Occlutech International AB
Heart Transplant
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.
- Trial name
- OPTIMIZE-HTx (NCT06942156)
- Testing
- Everolimus, Mycophenolate mofetil Tablet/Capsule
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Heart Failure
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure
This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.
- Trial name
- NCT00913653
- Testing
- LCZ696
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Heart Failure
CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)
The primary objective of this study is to evaluate the impact of Cardiac Contractility Modulation (CCM) therapy on the initiation and up-titration of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure (HF).
- Trial name
- NCT06580392
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Impulse Dynamics
Atrial Fibrillation
GLORIA-AF Registry Program (Phase I)
This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection of antithrombotic treatment…
- Trial name
- NCT01428765
- Where
- 62 sites in China, Croatia and 6 more
- Volunteers
- 1,096 people
- Sponsor
- Boehringer Ingelheim
Heart Diseases
Lumason® Infusion vs. Bolus Administrations
A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary…
- Trial name
- NCT06400004
- Testing
- Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON], Lumason
- Where
- 6 sites in United States
- Volunteers
- 106 people
- Sponsor
- Bracco Diagnostics, Inc
Right Heart Catheterization
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases.
- Trial name
- NCT05629533
- Testing
- SimpleSense
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
Coronary Disease, Coronary Artery Disease
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT00531011)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System, TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
Ischemic Congestive Heart Failure
Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements…
- Trial name
- NCT01502514
- Testing
- Fat Harvesting and Implantation of Adipose Derived Stem Cells
- Where
- Mexico
- Sponsor
- Ageless Regenerative Institute
Tachycardia, Ventricular
SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)
The present standard of care for the management of unstable ventricular tachycardia (VT) in the setting of chronic coronary artery disease is the placement of an implantable cardioverter defibrillator (ICD) after the initial…
- Trial name
- SMS (NCT00170287)
- Testing
- ICD Ablation plus VT-ablation, ICD Therapy
- Where
- 7 sites in Denmark, Germany
- Volunteers
- 116 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients
This study evaluates a new, non-invasive method for screening coronary artery disease (CAD) using seismocardiography (SCG) and gyrocardiography (GCG).
- Trial name
- HF-CAD-CCTA (NCT06880133)
- Testing
- Seismocardiography (SCG) and Gyrocardiography (GCG) Screening
- Where
- Uzbekistan
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Heart Force Medical Inc.
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Coronary Artery Disease
A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
Title: A randomized, double-blind, multi-centered, placebo-controlled trial to examine effects of of Heart-protecting Musk Pill on clinical outcomes in patients with chronic stable coronary artery disease Objective: To examine…
- Trial name
- NCT01897805
- Testing
- Heart-protecting Musk Pill
- Where
- 98 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Fabry Disease
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.
- Trial name
- NCT00864851
- Testing
- Replagal
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 44 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.